Immunotherapy News from the ASCO Annual Meeting | Conferences

'Very, Very Impressive' Results Seen With Ipilimumab/Nivolumab Combination

June 04, 2014

Phase I results presented in 2013 from a study combining ipilimumab with the anti-PD-1 antibody, nivolumab,1 showed a 40% objective response rate in 53 patients with advanced melanoma and a preliminary overall survival (OS) of 80%.